Overview

Combination Chemotherapy in Treating Pain in Hormone Refractory Metastatic Prostate Cancer

Status:
Completed
Trial end date:
2009-02-10
Target enrollment:
Participant gender:
Summary
RATIONALE: Some drugs used in chemotherapy can reduce the pain experienced by some people with cancer. Combining more than one drug may be more effective at reducing cancer pain. It is not known whether receiving combination chemotherapy with clodronate is more effective than receiving combination chemotherapy without clodronate for hormone refractory metastatic prostate cancer. PURPOSE: Randomized double-blinded phase III trial to compare the effectiveness of combination chemotherapy using mitoxantrone plus prednisone with or without clodronate in treating pain in patients with hormone refractory metastatic prostate cancer.
Phase:
Phase 3
Details
Lead Sponsor:
NCIC Clinical Trials Group
Treatments:
Clodronic Acid
Hormones
Mitoxantrone
Prednisone